Biomarkers of myocardial and renal dysfunction in chronic heart failure

Modern guidelines discuss in detail the treatment of patients with chronic heart failure (CHF). However, some aspects of biomarkers' use depending on comorbidity have not been sufficiently studied. The aim of this study was to investigate biomarkers of myocardial and renal dysfunction, including hypoxia-1-induced factor (HIF-1), in chronic heart failure, depending on the presence of chronic kidney disease (CKD). Materials and methods. The study included 80 patients with CHF (48 female, mean age 70.1±9.7 years). CHF was diagnosed according to the recommendations for the diagnosis and treatment of CHF of the Russian Society of Heart Failure Specialists (OSSN) and the Russian Society of Cardiology (RKO) - Clinical Guidelines. Chronic heart failure (CHF), 2016. CKD was diagnosed and classified according to the KDIGO guidelines (2012). HIF-1, N-terminal propeptide of natriuretic hormone type B (NT-proBNP), erythropoietin, cystatin C were tested in blood. Results. CKD was diagnosed in 49 (61.3%) patients. The level of HIF-1 was 0.06 (IQR 0.05; 0.08) ng/ml, NT-proBNP was 229.0 (IQR 136.1; 1205.9) pg/ml, erythropoietin was 6.93 (IQR 2.02; 11.6) mIU/ml. No difference was found in HIF-1 in CHF patients with and without CKD. However, in the group of patients with CHF and CKD, NT-proBNP and erythropoietin were an increased. A direct correlation was observed between the HIF-1 and NT-proBNP (r=0.25, p=0.024). Conclusion. HIF-1 in CHF is not associated with kidney function. Patients with chronic cardioranal syndrome have higher levels of erythropoietin and NT-proBNP. The nature of the relationship between erythropoietin and HIF-1 in chronic cardiorenal syndrome requires further study.

хроническая сердечная недостаточность, хроническая болезнь почек, эритропоэтин, фактор, индуцируемый гипоксией-1, цистатин С, chronic heart failure, chronic kidney disease, erythropoietin, Hypoxia Inducible Factor-1 (HIF-1), cystatin C

1. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; 8: 7-13. DOI: 10.15829/1560-4071-2016-8-7-13.

2. Chen J., Normand S.L., Wang Y. et al. National and regional trends in heart 2545 failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011; 306(15):1669-1678. ISSN 0098-7484.

3. Фомин И. В., Беленков Ю.Н., Мареев В.Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006; 7(3): 112-5. ISSN 1728-4651.

4. Porapakkham P., Porapakkham P., Zimmet H. et al. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010; 170(6): 507-14. DOI: 10.1001/archinternmed.2010.35.

5. Bao L., Chen Y., Lai H-T. et al. Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration. Nucleic Acids Research. 2018; 46(13): 6576-91. DOI: 10.1093/nar/gky449.

6. Ефремова Е.В., Шутов А.М., Макеева Е.Р., и др. Фактор, индуцируемый гипоксией-1 (HIF-1), как биомаркер острого повреждения почек у больных с острой декомпенсацией хронической сердечной недостаточности. Кардиология. 2019; 59(2S): 25-30. DOI: 10.18087/cardio.2533.

7. Fehr T., Ammann P., Garzoni D. et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004; 66(3): 1206-11. DOI: 10.1111/j.1523-1755.2004.00880.x.

8. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37(27): 2129-200. DOI: 10.1093/eurheartj/ehw128.

9. Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефрология. 2012; 4: 4-26. ISSN 2414-9322.

10. Ефремова Е.В., Шутов А.М., Сакаева Э.Р. Способ прогнозирования риска смерти у больных с хронической сердечной недостаточностью. Патент на изобретение. RU 2706975.

11. Lang R.M., Bierig M., Devereux R.B. et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2): 79-108. DOI: 10.1016/j.euje.2005.12.014.

12. Nagueh S.F., Smiseth O.A., Appleton C.P. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4): 277-314.DOI:10.1016/j. echo. 2016.01.011.

13. Ткачева О.Н., Рунихина Н.К., Остапенко В.С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017;30(2):236-42. ISSN 1561-9125.

14. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1): 67-74. ISSN 0025-7079.

15. Dimopoulos K., Diller G.P., Koltsida E. et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 2008; 117 (18): 2320-8. DOI: 10.1161/CIRCULATIONAHA.107.734921.

16. Tonelli M., Riella M. Chronic kidney disease and the aging population. Indian J Nephrol. 2014; 24(2): 71-74. DOI:10.4103/0971-4065.127881.

17. van Veldhuisen D.J., Ruilope L.M., Maisel A.S. et al. Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. European Heart Journal. 2016; 37(33): 2577-85. DOI: 10.1093/eurheartj/ehv588.

18. Dunlay S.M., Redfield M.M., Weston S.A. et al. Hospitalizations after heart failure 2548 diagnosis a community perspective. J Am Coll Cardiol. 2009; 54 (18): 1695-702. DOI: 10.1016/j.jacc.2009.08.019.

19. Ronco C., Haapio C., House A.A. et al. Саrdіоrеnаl syndrome. J Am Coll Cardiol 2008; 52(19): 1527-39. DOI: 10.1016/j.jacc.2008.07.051.

20. Nangaku M., Rosenberger C., Heyman S.N. et al. Regulation of hypoxia-inducible factor in kidney disease. Clinical and Experimental Pharmacology and Physiology. 2013; 40(2): 148-57. DOI: 10.1111/1440-1681.12005.

21. Gunaratnam L., Bonventre J.V. HIF in Kidney Disease and Development. Journal of the American Society of Nephrology. 2009; 20(9): 1877-87. DOI: 10.1681/ASN.2008070804.

22. Schaub J.A., Coca S.G., Moledina D.G. et al. Amino-terminal Pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: a systematic review and meta-analysis. JACC Heart Fail. 2015; 3: 977-89. DOI:10.1016/j.jchf.2015.07.014.

23. Li G., Lu W., Wu X. et al. Admission hypoxia-inducible factor 1α levels and in-hospital mortality in patients with acute decompensated heart failure. BMC Cardiovascular Disorders. 2015; 15(1). DOI: 10.1186/s12872-015-0073-6.

24. Hajjar V., Schreiber M.J. Does measuring natriuretic peptides have a role in patints with chronic kidney disease? Cleveland clinic journal of medicine. 2009; 76(8): 476-8. DOI: 10.3949/ccjm.76a.08065.

25. Park S., Cho G-Y., Kim S.G. et al. Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients. Critical Care. 2009; 13(3): R70 DOI: 10.1186/cc7878.

26. Руденко Т.Е., Кутырина И.М., Васильева М.П. Натрийуретические пептиды: диагностическое и прогностическое значения при хронической болезни почек. Клиническая нефрология. 2013; 2: 5-10. ISSN 2414-9322.

27. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008; 141(1): 14-31. DOI: 10.1111/j.1365-2141.2008.07014.x.

28. Steg P.G., Dabbous O.H., Feldman L.J., et al. Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes: Observations From the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004; 109(4): 494-9. DOI: 10.1161/01.CIR.0000109691.16944.DA.

29. Cernaro V., Coppolino G., Visconti L. et al. Erythropoiesis and chronic kidney disease-related anemia: From physiology to new therapeutic advancements. Med Res Rev. 2019; 39(2): 427-60. DOI: 10.1002/med.21527.

30. Artunc F., Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant. 2007; 22(10): 2900-8. DOI: 10.1093/ndt/gfm316.